Our research aims at understanding the mechanisms of action of novel biological pharmaceuticals on tumor cells.
We are focusing on extra- and intracellularly functional antibodies, and fragments to tailor the antibody-target interaction, as well as to widen the druggable proteome for antibody therapeutics.
We also aim at developing new drug delivery technologies to target tumors that for one reason or another are difficult to reach by drugs because of, for example, low exposure levels, metabolism, or adverse toxicity.
A third research interest concerns a novel proteomics methodology for characterization of membrane proteins aimed at epitope discovery for antibody therapeutics targeting ion channels, and GPCRs.
|Kent Jardemark||Senior Lecturer||joint leadership|
|Owe Orwar||Senior Researcher||joint leadership|
|Joseph Bruton||Senior Researcher|
|Neslihan Dikmenoglu Falkmarken||Associated|
|Niklas Ivarsson||Senior Researcher|
|Oscar Jungholm||PhD Student|
|Monica Marcus||Senior Lab Manager|
- Oblique Therapeutics AB
Microfluidic flow cell for sequential digestion of immobilized proteoliposomes.
Anal. Chem. 2012 Jul;84(13):5582-8
Effect of cholesterol depletion on the pore dilation of TRPV1.
Mol Pain 2013 Jan;9():1
A multifunctional pipette for localized drug administration to brain slices.
J. Neurosci. Methods 2013 Oct;219(2):292-6
Probing enzymatic activity inside single cells.
Anal. Chem. 2013 Nov;85(21):10126-33
Probing structure and function of ion channels using limited proteolysis and microfluidics.
J. Am. Chem. Soc. 2014 Oct;136(42):14875-82
Spatial characterization of a multifunctional pipette for drug delivery in hippocampal brain slices.
J. Neurosci. Methods 2015 Feb;241():132-6